EN
SINOVAC's Hepatitis A Vaccine Healive® Approved in Kyrgyzstan
February 8, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its inactivated hepatitis A vaccine, Healive® has been approved by the Ministry of Health of the Kyrgyz Republic, the company's first direct authorization of a vaccine for market use in Kyrgyzstan.
The approval adds a powerful tool to the nation's fight against hepatitis transmission and infection. Once named a focus country for viral hepatitis by the World Health Organization (WHO), Kyrgyzstan has since taken measures to prevent and control the infectious disease. Hepatitis B vaccine has been included in Kyrgyzstan's national vaccination schedule since 2000, but hepatitis A vaccine is only available in the private sector for self-purchase.
According to the Department of Disease Prevention and State Sanitary and Epidemiological Surveillance, the first three quarters of 2022 saw a notable rise in reported cases of acute viral hepatitis in Kyrgyzstan. From January to September, 1,501 acute viral hepatitis cases were registered, a 25% increase compared to the same period in 2021.
Out of those cases, 1,388 hepatitis A cases contributed to 92.5% of the total incidences during that time frame, representing a year-on-year increase of 29%. A more accessible supply of hepatitis A vaccines in Kyrgyzstan will ensure local communities are better protected and will build on the country’s success lowering transmission as the dominant cause of viral hepatitis cases.
Healive®, a SINOVAC flagship product, is the first and only hepatitis A vaccine from China pre-qualified by the WHO. It offers sustained protection for at least 30 years after full-course immunization, based on statistical modeling1.
The vaccine has been registered in 23 countries and organizations around the world, including Kyrgyzstan, and is currently authorized for administration in more than 30 countries and areas.
Healive® and SINOVAC's varicella vaccine, another WHO prequalified vaccine, can be administered simultaneously to children 1 year of age, to enhance vaccination efficiency and save cost and time for parents and doctors. According to a recent study2, delivering the doses together offers additional benefits by reducing pain and establishing earlier immunity.
Reference:
About SINOVAC
Sinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company's website at www.sinovac.com.
Contact:
Sinovac Biotech Ltd.
PR Team
pr@sinovac.com
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.